Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029

Page: 131

Published Date: 21 Oct 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Short-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 14300 million by 2029, rising at a market growth of 6.1% CAGR during the forecast period (2023-2029).

The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

This report studies the global Short-acting Recombinant Human Erythropoietin Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Short-acting Recombinant Human Erythropoietin Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Short-acting Recombinant Human Erythropoietin Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Short-acting Recombinant Human Erythropoietin Drugs total production and demand, 2018-2029, (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs total production value, 2018-2029, (USD Million)
Global Short-acting Recombinant Human Erythropoietin Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Short-acting Recombinant Human Erythropoietin Drugs domestic production, consumption, key domestic manufacturers and share
Global Short-acting Recombinant Human Erythropoietin Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Short-acting Recombinant Human Erythropoietin Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Short-acting Recombinant Human Erythropoietin Drugs market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Short-acting Recombinant Human Erythropoietin Drugs Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Short-acting Recombinant Human Erythropoietin Drugs Market, Segmentation by Type
    Epoetin-alfa
    Epoetin-beta
    Darbepoetin-alfa
    Others

Global Short-acting Recombinant Human Erythropoietin Drugs Market, Segmentation by Application
    Anemia
    Kidney Disorders
    Others

Companies Profiled:
    Amgen
    Johnson & Johnson
    Roche
    Kyowa Kirin
    LG Chem
    Daewoong Pharmaceutical
    Wockhardt
    CJ Healthcare
    3SBio
    Kexing Biopharm
    Harbin Pharmaceutical Group
    Beijing Four Rings Bio-Pharmaceutical

Key Questions Answered
1. How big is the global Short-acting Recombinant Human Erythropoietin Drugs market?
2. What is the demand of the global Short-acting Recombinant Human Erythropoietin Drugs market?
3. What is the year over year growth of the global Short-acting Recombinant Human Erythropoietin Drugs market?
4. What is the production and production value of the global Short-acting Recombinant Human Erythropoietin Drugs market?
5. Who are the key producers in the global Short-acting Recombinant Human Erythropoietin Drugs market?

Table of Contents

1 Supply Summary
    1.1 Short-acting Recombinant Human Erythropoietin Drugs Introduction
    1.2 World Short-acting Recombinant Human Erythropoietin Drugs Supply & Forecast
        1.2.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018 & 2022 & 2029)
        1.2.2 World Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
        1.2.3 World Short-acting Recombinant Human Erythropoietin Drugs Pricing Trends (2018-2029)
    1.3 World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (Based on Production Site)
        1.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2029)
        1.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2029)
        1.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2029)
        1.3.4 North America Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
        1.3.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
        1.3.6 China Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
        1.3.7 Japan Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Short-acting Recombinant Human Erythropoietin Drugs Major Market Trends

2 Demand Summary
    2.1 World Short-acting Recombinant Human Erythropoietin Drugs Demand (2018-2029)
    2.2 World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region
        2.2.1 World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023)
        2.2.2 World Short-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029)
    2.3 United States Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
    2.4 China Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
    2.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
    2.6 Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
    2.7 South Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
    2.8 ASEAN Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
    2.9 India Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)

3 World Short-acting Recombinant Human Erythropoietin Drugs Manufacturers Competitive Analysis
    3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023)
    3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023)
    3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023)
    3.4 Short-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Short-acting Recombinant Human Erythropoietin Drugs in 2022
        3.5.3 Global Concentration Ratios (CR8) for Short-acting Recombinant Human Erythropoietin Drugs in 2022
    3.6 Short-acting Recombinant Human Erythropoietin Drugs Market: Overall Company Footprint Analysis
        3.6.1 Short-acting Recombinant Human Erythropoietin Drugs Market: Region Footprint
        3.6.2 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
        3.6.3 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison
        4.1.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Comparison
        4.2.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison
        4.3.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
    4.5 China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share
        4.5.1 China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
        4.5.3 China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
    4.6 Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)

5 Market Analysis by Type
    5.1 World Short-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Epoetin-alfa
        5.2.2 Epoetin-beta
        5.2.3 Darbepoetin-alfa
        5.2.4 Others
    5.3 Market Segment by Type
        5.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2029)
        5.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2029)
        5.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Short-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Anemia
        6.2.2 Kidney Disorders
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2029)
        6.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2029)
        6.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Amgen
        7.1.1 Amgen Details
        7.1.2 Amgen Major Business
        7.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.1.4 Amgen Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Amgen Recent Developments/Updates
        7.1.6 Amgen Competitive Strengths & Weaknesses
    7.2 Johnson & Johnson
        7.2.1 Johnson & Johnson Details
        7.2.2 Johnson & Johnson Major Business
        7.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Johnson & Johnson Recent Developments/Updates
        7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
    7.3 Roche
        7.3.1 Roche Details
        7.3.2 Roche Major Business
        7.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.3.4 Roche Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 Roche Recent Developments/Updates
        7.3.6 Roche Competitive Strengths & Weaknesses
    7.4 Kyowa Kirin
        7.4.1 Kyowa Kirin Details
        7.4.2 Kyowa Kirin Major Business
        7.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Kyowa Kirin Recent Developments/Updates
        7.4.6 Kyowa Kirin Competitive Strengths & Weaknesses
    7.5 LG Chem
        7.5.1 LG Chem Details
        7.5.2 LG Chem Major Business
        7.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 LG Chem Recent Developments/Updates
        7.5.6 LG Chem Competitive Strengths & Weaknesses
    7.6 Daewoong Pharmaceutical
        7.6.1 Daewoong Pharmaceutical Details
        7.6.2 Daewoong Pharmaceutical Major Business
        7.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Daewoong Pharmaceutical Recent Developments/Updates
        7.6.6 Daewoong Pharmaceutical Competitive Strengths & Weaknesses
    7.7 Wockhardt
        7.7.1 Wockhardt Details
        7.7.2 Wockhardt Major Business
        7.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.7.4 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Wockhardt Recent Developments/Updates
        7.7.6 Wockhardt Competitive Strengths & Weaknesses
    7.8 CJ Healthcare
        7.8.1 CJ Healthcare Details
        7.8.2 CJ Healthcare Major Business
        7.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 CJ Healthcare Recent Developments/Updates
        7.8.6 CJ Healthcare Competitive Strengths & Weaknesses
    7.9 3SBio
        7.9.1 3SBio Details
        7.9.2 3SBio Major Business
        7.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.9.4 3SBio Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 3SBio Recent Developments/Updates
        7.9.6 3SBio Competitive Strengths & Weaknesses
    7.10 Kexing Biopharm
        7.10.1 Kexing Biopharm Details
        7.10.2 Kexing Biopharm Major Business
        7.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.10.5 Kexing Biopharm Recent Developments/Updates
        7.10.6 Kexing Biopharm Competitive Strengths & Weaknesses
    7.11 Harbin Pharmaceutical Group
        7.11.1 Harbin Pharmaceutical Group Details
        7.11.2 Harbin Pharmaceutical Group Major Business
        7.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
        7.11.6 Harbin Pharmaceutical Group Competitive Strengths & Weaknesses
    7.12 Beijing Four Rings Bio-Pharmaceutical
        7.12.1 Beijing Four Rings Bio-Pharmaceutical Details
        7.12.2 Beijing Four Rings Bio-Pharmaceutical Major Business
        7.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
        7.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
        7.12.6 Beijing Four Rings Bio-Pharmaceutical Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Short-acting Recombinant Human Erythropoietin Drugs Industry Chain
    8.2 Short-acting Recombinant Human Erythropoietin Drugs Upstream Analysis
        8.2.1 Short-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
        8.2.2 Main Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Short-acting Recombinant Human Erythropoietin Drugs Production Mode
    8.6 Short-acting Recombinant Human Erythropoietin Drugs Procurement Model
    8.7 Short-acting Recombinant Human Erythropoietin Drugs Industry Sales Model and Sales Channels
        8.7.1 Short-acting Recombinant Human Erythropoietin Drugs Sales Model
        8.7.2 Short-acting Recombinant Human Erythropoietin Drugs Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2023)
    Table 5. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2024-2029)
    Table 6. World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2023) & (K Units)
    Table 7. World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2024-2029) & (K Units)
    Table 8. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2023)
    Table 9. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2024-2029)
    Table 10. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2023) & (US$/Unit)
    Table 11. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2024-2029) & (US$/Unit)
    Table 12. Short-acting Recombinant Human Erythropoietin Drugs Major Market Trends
    Table 13. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023) & (K Units)
    Table 15. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Short-acting Recombinant Human Erythropoietin Drugs Producers in 2022
    Table 18. World Short-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Short-acting Recombinant Human Erythropoietin Drugs Producers in 2022
    Table 20. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
    Table 22. World Short-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Short-acting Recombinant Human Erythropoietin Drugs Production Site of Key Manufacturer
    Table 24. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
    Table 25. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
    Table 26. Short-acting Recombinant Human Erythropoietin Drugs Competitive Factors
    Table 27. Short-acting Recombinant Human Erythropoietin Drugs New Entrant and Capacity Expansion Plans
    Table 28. Short-acting Recombinant Human Erythropoietin Drugs Mergers & Acquisitions Activity
    Table 29. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
    Table 37. China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
    Table 42. Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
    Table 47. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2023) & (K Units)
    Table 49. World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2024-2029) & (K Units)
    Table 50. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2023) & (US$/Unit)
    Table 53. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2024-2029) & (US$/Unit)
    Table 54. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2023) & (K Units)
    Table 56. World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2024-2029) & (K Units)
    Table 57. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2023) & (US$/Unit)
    Table 60. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2024-2029) & (US$/Unit)
    Table 61. Amgen Basic Information, Manufacturing Base and Competitors
    Table 62. Amgen Major Business
    Table 63. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 64. Amgen Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Amgen Recent Developments/Updates
    Table 66. Amgen Competitive Strengths & Weaknesses
    Table 67. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
    Table 68. Johnson & Johnson Major Business
    Table 69. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 70. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Johnson & Johnson Recent Developments/Updates
    Table 72. Johnson & Johnson Competitive Strengths & Weaknesses
    Table 73. Roche Basic Information, Manufacturing Base and Competitors
    Table 74. Roche Major Business
    Table 75. Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 76. Roche Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Roche Recent Developments/Updates
    Table 78. Roche Competitive Strengths & Weaknesses
    Table 79. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
    Table 80. Kyowa Kirin Major Business
    Table 81. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 82. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Kyowa Kirin Recent Developments/Updates
    Table 84. Kyowa Kirin Competitive Strengths & Weaknesses
    Table 85. LG Chem Basic Information, Manufacturing Base and Competitors
    Table 86. LG Chem Major Business
    Table 87. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 88. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. LG Chem Recent Developments/Updates
    Table 90. LG Chem Competitive Strengths & Weaknesses
    Table 91. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 92. Daewoong Pharmaceutical Major Business
    Table 93. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 94. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Daewoong Pharmaceutical Recent Developments/Updates
    Table 96. Daewoong Pharmaceutical Competitive Strengths & Weaknesses
    Table 97. Wockhardt Basic Information, Manufacturing Base and Competitors
    Table 98. Wockhardt Major Business
    Table 99. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 100. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Wockhardt Recent Developments/Updates
    Table 102. Wockhardt Competitive Strengths & Weaknesses
    Table 103. CJ Healthcare Basic Information, Manufacturing Base and Competitors
    Table 104. CJ Healthcare Major Business
    Table 105. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 106. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. CJ Healthcare Recent Developments/Updates
    Table 108. CJ Healthcare Competitive Strengths & Weaknesses
    Table 109. 3SBio Basic Information, Manufacturing Base and Competitors
    Table 110. 3SBio Major Business
    Table 111. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 112. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 113. 3SBio Recent Developments/Updates
    Table 114. 3SBio Competitive Strengths & Weaknesses
    Table 115. Kexing Biopharm Basic Information, Manufacturing Base and Competitors
    Table 116. Kexing Biopharm Major Business
    Table 117. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 118. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 119. Kexing Biopharm Recent Developments/Updates
    Table 120. Kexing Biopharm Competitive Strengths & Weaknesses
    Table 121. Harbin Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
    Table 122. Harbin Pharmaceutical Group Major Business
    Table 123. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 124. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 125. Harbin Pharmaceutical Group Recent Developments/Updates
    Table 126. Beijing Four Rings Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 127. Beijing Four Rings Bio-Pharmaceutical Major Business
    Table 128. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
    Table 129. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 130. Global Key Players of Short-acting Recombinant Human Erythropoietin Drugs Upstream (Raw Materials)
    Table 131. Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
    Table 132. Short-acting Recombinant Human Erythropoietin Drugs Typical Distributors
List of Figure
    Figure 1. Short-acting Recombinant Human Erythropoietin Drugs Picture
    Figure 2. World Short-acting Recombinant Human Erythropoietin Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Short-acting Recombinant Human Erythropoietin Drugs Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
    Figure 5. World Short-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029) & (US$/Unit)
    Figure 6. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2029)
    Figure 7. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2029)
    Figure 8. North America Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
    Figure 9. Europe Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
    Figure 10. China Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
    Figure 11. Japan Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
    Figure 12. Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 15. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share by Region (2018-2029)
    Figure 16. United States Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 17. China Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 18. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 19. Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 22. India Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Short-acting Recombinant Human Erythropoietin Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Short-acting Recombinant Human Erythropoietin Drugs Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Short-acting Recombinant Human Erythropoietin Drugs Markets in 2022
    Figure 26. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
    Figure 30. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
    Figure 32. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type in 2022
    Figure 34. Epoetin-alfa
    Figure 35. Epoetin-beta
    Figure 36. Darbepoetin-alfa
    Figure 37. Others
    Figure 38. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Type (2018-2029)
    Figure 39. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type (2018-2029)
    Figure 40. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029) & (US$/Unit)
    Figure 41. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 42. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application in 2022
    Figure 43. Anemia
    Figure 44. Kidney Disorders
    Figure 45. Others
    Figure 46. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Application (2018-2029)
    Figure 47. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application (2018-2029)
    Figure 48. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029) & (US$/Unit)
    Figure 49. Short-acting Recombinant Human Erythropoietin Drugs Industry Chain
    Figure 50. Short-acting Recombinant Human Erythropoietin Drugs Procurement Model
    Figure 51. Short-acting Recombinant Human Erythropoietin Drugs Sales Model
    Figure 52. Short-acting Recombinant Human Erythropoietin Drugs Sales Channels, Direct Sales, and Distribution
    Figure 53. Methodology
    Figure 54. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical

Related Reports

Global Short-acting Recombinant Human Erythropoietin Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Short-acting Recombinant Human Erythropoietin Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 21 Oct 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 9433.4 million in 2022 and is forecast to a readjusted size of USD 14300 million by 2029 with a CAGR of 6.1% during review period.

Global Short-acting Recombinant Human Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Short-acting Recombinant Human Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 19 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at USD 9433.4 million in 2023 and is forecast to a readjusted size of USD 14300 million by 2030 with a CAGR of 6.1% during review period.

Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2024-2030

Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2024-2030

date 06 Mar 2024

date Pharma & Healthcare

The global Short-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 14300 million by 2030, rising at a market growth of 6.1% CAGR during the forecast period (2024-2030).

Product Tags

Short-acting Recombinant Human Erythropoietin Drugs

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>